Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

This study has been completed.

Study NCT00071396 Information provided by M.D. Anderson Cancer Center

First Received: October 21, 2003 Last Updated: July 27, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	August 2007
Primary Completion Date:	September 2006 (Final data collection date for primary outcome measure)